Instructions to Authors

General Information
Publication Ethics and Malpractice Statement
Authorship
Co-authorship verification
Plagiarism and redundant publication
Peer Review Process
Appealing a decision
Manuscript Submission
How to Submit
Guidelines for Presentation
Editorials
Original Articles
Reviews
Trial Design Papers
Correspondence/letters
Current Opinion
Viewpoint
PharmaPulse
Case Reports
Figures
Tables
References
Supplementary material
Permission to Reproduce Figures
Licence to Publish
Open Access option for Authors
Pre-submission Language Editing
Format Free Submissions
Publication of author’s accepted manuscript
Proofs
Preprints and self-archiving
Author Toll-Free Link
Post-publication corrections
Retractions
Contact us

General Information

European Heart Journal – Cardiovascular Pharmacotherapy is an official Journal of the European Society of Cardiology (ESC). It accepts manuscripts from all parts of the world by members and non-members of the Society. More about the journal.

The journal follows the recommendations of the International Committee of Medical Journal Editors (ICMJE).

Papers that do not adhere to these instructions and policies below will be returned for revision before assessment.

Publication Ethics and Malpractice Statement

Publication ethics

European Heart Journal – Cardiovascular Pharmacotherapy and Oxford University Press are members of the Committee on Publication Ethics (COPE). This journal follows the guidance provided in the Core Practices issued by COPE. The journal also subscribes to the International Committee of Medical Journal Editors (ICJME) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals. Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals. The Journal expects all parties involved in the publication of content in European Heart Journal – Cardiovascular Pharmacotherapy (the publisher, editors, authors, and reviewers) to follow these guidelines on best practice and publication ethics. The Editors are further supported by the ESC Publication Ethics Committee.

In addition to the above, submitted authors and reviewers should consider the guidelines referenced below for patient consent, animal experimentation, registration of clinical trials, conflict of interest, and authorship.

The Journal is committed to investigating all cases of alleged editor, author, and reviewer misconduct arising from its activities. The Journal will follow COPE Guidelines in all cases.

Human subjects and patient consent

Research submitted to the journal must comply with the Declaration of Helsinki. The research protocol must be approved by the locally appointed ethics committee. The informed consent of patients or volunteers (or their guardian), in particular when there is identifying information, must be obtained. These facts must be indicated in the manuscript.

Authors should observe high standards with respect to publication ethics as set out by the Committee on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE) recommendations for reporting about patients. Patients have a right to privacy that should not be infringed without prior informed consent.

Identifying information should not be published in written descriptions, photographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) has given written informed consent for publication. Informed consent for this purpose requires the patient be shown the manuscript to be published.

Identifying details should be omitted if they are not essential, but patient data should never be altered or falsified to attain anonymity. We understand that complete anonymity is difficult to achieve. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.

Animal experimentation

The journal aims for detailed and high quality reporting of animal experiments and suggests authors follow the ARRIVE guidelines when preparing their manuscript. Authors may be required to provide evidence that they obtained ethical and /or legal approval prior to conducting the research.

Registration of clinical trials

All clinical trials, in particular those involving pharmaceuticals, devices, or aspects relating to nutrition, should be registered prospectively in publicly accessible databases (such as ClinicalTrials and ClinicalTrialsRegister) and the paper should include registration numbers and the name of the register. Clinical trials must be reported according to CONSORT guidelines.

Statistics

The application of adequate statistical methods is required for publication in European Heart Journal Cardiovascular Pharmacotherapy. The Journal advises authors to ‘be as simple as possible, but as sophisticated as needed’. For example, clinical trials with their formalized framework must meet more specific statistical standards than pathophysiological studies. Authors are advised to include absolute risk as well as relative risk where possible. For studies with a sophisticated design, the collaboration of a professional statistician is recommended.

Authors should refer to the following guidance before submitting: Statistical Analysis in the European Heart Journal Quality Standards document

Availability of Data and Materials

Where ethically feasible, European Heart Journal – Cardiovascular Pharmacotherapy strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. Authors are required to include a Data Availability Statement in their article.

We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. Information on general repositories for all data types, and a list of recommended repositories by subject area, is available here.

Data Availability Statement

The inclusion of a Data Availability Statement is a requirement for articles published in European Heart Journal – Cardiovascular Pharmacotherapy. Data Availability Statements provide a standardised format for readers to understand the availability of data underlying the research results described in the article. The statement may refer to original data generated in the course of the study or to third-party data analysed in the article. The statement should describe and provide means of access, where possible, by linking to the data or providing the required unique identifier.

More information and example Data Availability statements can be found here.

Data Citation

European Heart Journal – Cardiovascular Pharmacotherapy supports the Force 11 Data Citation Principles and requires that all publicly available datasets be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI). Data citations should include the minimum information recommended by DataCite:

[dataset]* Authors, Year, Title, Publisher (repository or archive name), Identifier

*The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly identify and tag the citation. This tag will be removed from the citation published in the reference list.

Conflict of interest

It is the responsibility of each co-author to declare any conflicts of interests (COI) on submission and it is the responsibility of the corresponding author to ensure that the Journal receives all declarations from each co-author. All authors must declare any conflicts of interest. indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. A detailed definition of conflicts of interests can be found on OUP's Publication Ethics page.

Instructions for the author/s:

The corresponding author submits their conflicts of interest declaration by answering the mandatory COI questions in the submission system at the time of submission.
Any co-authors listed will be contacted by email to confirm their co-authorship and to submit their COI declaration by answering a series of mandatory questions in the submission system.
Authors are still required to provide a response to the COI questions even if there are no conflicts of interest to declare (state “none declared”).
The corresponding author must, at revision stage (at the latest), submit a concise and accurate summary of any conflicts of interest declared under the “Disclosures” header. If there are no conflicts of interest, state “Conflict of interest: none declared”. The text under “Disclosures” will be included at the end of the article when published.

To ensure that all manuscripts receive unbiased evaluation, it is the Journal’s policy that papers where an EHJ-CVP Editor is an author or contributor will be assigned to another handling editor (who is not at the same institution). This also applies for papers where an Editor has declared any other conflict of interest. The handling editor will oversee the peer review and decision-making process. For articles in which the handling editor or reviewer has a conflict of interest, they are obliged to withdraw from the process.

Instructions for the submitting author:

When submitting your paper please indicate in your cover letter if an Editor from EHJ-CVP is a co-author on the manuscript or has been a contributor to the manuscript in any other way.
Please include the following declaration in a section of the submitted manuscript entitled “Disclosures”: ‘[author initials, e.g. X.X] is an Editor of European Heart Journal – Cardiovascular Pharmacotherapy and was not involved in the peer review process or publication decision’.

Authorship

All individuals listed as authors should qualify for authorship and should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Authors included in the manuscript must meet all of the following conditions, as specified in the guidelines of the International Committee of Medical Journal Editors (ICJME): 1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; 2) drafted the work or reviewed it critically for important intellectual content; 3) given final approval of the version to be published; and 4) agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All individuals who meet the authorship criteria listed above must be listed as authors. The Journal considers all forms of ghost authorship, in which an individual contributes in the role of an author (according to the criteria above) but is not listed as an author on the manuscript, as unethical and unacceptable.

Individuals who do not meet the above authorship criteria should not be listed as authors. The Journal considers all forms of guest or gift authorship, in which individuals are included though they do not meet the above criteria, as unethical and unacceptable. However, it may be appropriate to list some individuals in an acknowledgement section.

For further information about authorship, please refer to the ICMJE recommendations.

Artificial Intelligence

Natural language processing tools driven by artificial intelligence (AI) do not qualify as authors, and the Journal will screen for them in author lists. The use of AI (for example, to help generate content or images, write code, process data, or for translation) should be disclosed in a cover letter at the point of submission and explained in full in a Methods or Acknowledgements section in the manuscript. Please see the COPE position statement on Authorship and AI for more details.

Co-Authorship Verification

The corresponding author is responsible for providing the full list of co-authors on the manuscript. The co-authors will receive an email asking them to verify their contribution to the manuscript. The corresponding author is responsible for ensuring that this step is completed.

Plagiarism and Redundant Publication

COPE defines plagiarism as ‘when somebody presents the work of others (data, words or theories) as if they were his/her own and without proper acknowledgement’.

COPE defines redundant publication as ‘when a published work (or substantial sections from a published work) is/are published more than once (in the same or another language) without adequate acknowledgment of the source/cross-referencing/justification or when the same (or substantially overlapping) data is presented in more than one publication without adequate cross-referencing/justification, particularly when this is done in such a way that reviewers/readers are unlikely to realise that most or all the findings have been published before”.

Manuscripts submitted to EHJ-CVP may be screened with iThenticate anti-plagiarism software to detect and prevent plagiarism and redundant publication. Any manuscript may be screened, especially if there is reason to suppose part or all the text has been previously published. Prior to final acceptance any manuscript that has not already been screened may be put through iThenticate. More information about iThenticate is available here.

Peer Review Process

All material submitted to European Heart Journal - Cardiovascular Pharmacotherapy will be reviewed by the Editorial team. Papers may be rejected without full peer review, remaining papers will be sent for external peer review.

The journal operates a single-anonymised peer review process, meaning that the Authors' identities are known to the Editor and the Reviewers, but that the Reviewers’ identities are known only to the Editor and are hidden from the Authors. The journal aims to provide rapid peer review with papers receiving a first decision within an average of 9 days.
During the online submission process, authors have the opportunity to name preferred or non-preferred referees, or both, but the Editor is under no obligation to act upon any suggestions.

Authors may be requested to produce the data on which their manuscript is based (or associated documents, e.g. ethical approval letter) by the Editor(s) or their assignee for examination. Authors must comply with such a request.

EHJ-CVP has partnered with the Web of Science Reviewer Recognition Service (formerly 'Publons'). This is a third party service that seeks to track, verify and give credit for peer review. Reviewers for EHJ-CVP can opt in to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Web of Science Reviewer Recognition Service website.

Appealing a decision

If the authors have reason to believe that the review process or final decision has not been fair or well-informed, the authors may submit an appeal via email to the Editorial Office (ehjcvp.editorialoffice@oup.com). The appeal should be provided in a word document as an attachment to the email and should not exceed 2 pages. Appeals can be submitted within 1 month of the final decision on the manuscript. Appeals received after this date will not be considered.

An appeal should include: author name; manuscript title; manuscript ID; an explanation of why the decision rendered was unfair or not merited; specific comments in relation to the reviewer reports; email and contact details.

The appeal will be considered carefully by the Editor-in-Chief and the Editorial Board. The Journal will consider one appeal per manuscript.

Confidentiality

All submitted manuscripts are treated as confidential documents. They may only be reviewed by the Editors, Editorial Office staff and assigned peer reviewers unless otherwise permitted by the authors. By accepting to review a manuscript, referees agree to treat the material as confidential.

Articles submitted by the Editors or Associate Editors

To ensure original research submitted by the Editor/Associate Editors receives an unbiased evaluation, it is the Journal’s policy that their paper will be assigned to another Associate Editor (who is not at the same institute) to be overseen during the decision-making process.
For articles in which the Editor/Associate Editor has a conflict of interest, they are obliged to withdraw from the decision-making process.

Any manuscript in which the Editor-in-Chief is an author or contributor will be assigned to an external Guest Editor. Papers that are handled by a Guest Editor will include a statement in the article.

The corresponding author should indicate in the cover letter if an Editor or Associate Editor from European Heart Journal – Cardiovascular Pharmacotherapy is a co-author or contributor to the manuscript.

Manuscript Submission

The Journal will consider submissions within its scope providing

it is the original work of the authors and does not duplicate any previously published work, including the work of the authors;
it is not under consideration or accepted for publication in any journal other than EHJ-CVP;
it has not been published in any other journal; and
it contains nothing abusive, defamatory, libelous, obscene, fraudulent, or illegal.

Authors should observe high ethical standards and obey publication best practices. The following are all unacceptable:

data falsification or fabrication
plagiarism, including duplicate publication of the author’s own work without proper citation
redundant publication
misappropriation of work

The Journal expects all authors to have read and understood the editorial policies of the Journal prior to submission.
The Journal treats any case of ethical or publication malpractice very seriously. Any cases will be addressed in accordance with the Committee on Publication Ethics (COPE) Guidelines. In addition, the Journal is supported by the ESC Journal Family Ethics Committee.

ESC Manuscript Transfer

Authors submitting to the Journal will be given the opportunity to indicate whether their manuscript can be considered for transfer to another ESC Journal if European Heart Journal – Cardiovascular Pharmacotherapy is unable to consider their manuscript further.

If authors agree to be considered for transfer, and the manuscript is selected for transfer, authors are not required to resubmit their manuscript and any reviewer comments will be transferred, resulting in a reduced time to decision.

How to submit

All papers for regular issues should be submitted online. This will take you to the online submission and editorial system for European Heart Journal - Cardiovascular Pharmacotherapy. Please follow the instructions given on screen. If the corresponding author has not previously submitted to the Journal, they will need to register for an account.

Please note that if you are submitting a paper following a 'Reject de novo' decision, please include a response to reviewer comments from the initial peer review with your new submission and a copy of the tracked version of the manuscript.

For any queries during the submission and peer review process please contact the editorial office (ehjcvp.editorialoffice@oup.com).

We encourage all authors to add their ORCiDs to their Editorial Manager accounts and include their ORCIDs as part of the submission process. If you do not already have one you can register for an ORCID iD.

Guidelines for Presentation

Manuscripts should be written in the English language (using either American or British spelling). They should be typed, double spaced using 2.5 cm wide margins all around. The text is arranged as follows: (1) title page, (2) abstract and keywords, (3) introduction, (4) methods, (5) results, (6) discussion, (7) acknowledgements, (8) references, (9) appendices, (10) text tables, (11) figure legends. Please refer to the ICMJE recommendations on manuscript preparation and submission. The format may be altered for review articles, if necessary.

The title page bears: (a) full title, (b) all authors names and affiliations, (c) the institution(s) where the work was done, (d) the mailing address and email address of the corresponding author.

Please ensure that the title of your paper is fully descriptive of the content of the paper.

Abstracts

An abstract (maximum 250 words) is typed double spaced on a separate page. The abstract is structured under the headings (1) aims, (2) methods and results, (3) conclusion.

Graphical abstracts

Guidance on how to create an effective graphical abstract

Authors of original articles, review articles and trial design papers are encouraged to submit a graphical abstract (schematic figure) as part of the article, in addition to the text abstract. The graphical abstract should clearly summarize the focus and findings of the article, and will be published as part of the article online and in PDF. Graphical abstracts help communicate the key messages in your paper to readers in a clear and immediate way. They are well-suited to sharing on social media, which helps disseminate research more widely and allows readers to easily identify papers that are of interest to them. The graphical abstract should be submitted for peer review as a separate file, selecting the appropriate file-type designation in the journal’s online submission system. You may select an illustration from the main paper to function as the Graphical Abstract. Either way, the file should be clearly named, e.g. graphical_abstract.tiff.

Authors are strongly encouraged to supply rough drafts of their graphical abstracts and key illustrations at submission stage. If your paper is accepted, then a leading medical illustration company may be engaged to redraw your graphics and the ESC will bear the cost of this service.
Please adhere to the following guidelines when preparing your graphical abstract:

Size: 12.5 cm x 18.0 cm (height x width)
Minimum resolution: 300 dpi (the dpi of an image can usually be found by right-clicking on an image file and selecting ‘Properties’)
Font: use a sans serif font. Gill Sans is preferred but Myriad Pro, Arial, or Helvetica are acceptable.
Font size: text should be 10-12 points, but no smaller than 8 points
A figure legend should be included for the graphic element, which should define any abbreviations. This should be given in the ‘Legends’ section of the manuscript

Further guidance on appropriate file format and resolution for graphics is available.

Further guidance on how to create an effective graphical abstract.

Keywords

No more than six key words are required.

Units and Abbreviations

Abbreviations other than standard SI units of measurement are not used.

Acknowledgements

Substantive contributions of individuals should be noted in an Acknowledgements section and entered before the Conflict of Interest (COI) statement.

Funding

Details of all funding sources for the work in question should be given in a separate section entitled 'Funding'. This should appear before the 'Acknowledgements' section.

The following rules should be followed:

The sentence should begin: ‘This work was supported by …’
The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 sub-institutions) or 'NCI at NIH’ (full RIN-approved list of UK funding agencies)
Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX CDXXXXXX]’
Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]’
Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)
Where individuals must be specified for certain sources of funding, the following text should be added after the relevant agency or grant number 'to [author initials]'.

An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789].

Oxford Journals will deposit all NIH-funded articles in PubMed Central. Authors must ensure that manuscripts are clearly indicated as NIH-funded using the guidelines above.

Crossref Funding Data Registry

In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process or to find out more about CHORUS, visit the CHORUS initiative.

Editorials

All editorials should be limited to 1500 words (including references, figure legends and tables), with a maximum of 15 references.

Original Articles

Original articles should not exceed 5000 words (including references, figure legends and tables) and a maximum of 50 references.

Reviews

Reviews should not exceed 5000 words (excluding references and the text in figure legends and tables).

Trial Design Papers

EHJ-CVP welcomes papers that describe the design of studies, large clinical trials, or registries in cardiology. The trials should have ethical approval, preferably be ongoing, with results expected within 12-18 months.

These papers should include the following sections in the following order: abstract, introduction, methods/design, discussion. EHJ-CVP strongly encourages authors to provide a graphical abstract that describes the trial design or methods. These papers should not exceed 3,000 words (including references, figure legends, and tables) and should have no more than 50 references.

Correspondence/Letters

Letters may include up to 1000 words (including references, figure legends and tables). Authors may include up to 1 figure/table and up to 10 references. These should have no abstract and no sub-headings. Type double-spaced. Letters should not include original research findings or data.

Current Opinion

Current Opinion papers should not exceed 2,500 words (including references, figure legends and tables). Authors may include up to 20 references only.

Viewpoint

Short opinion papers authored by leading experts, addressing a wide range of topics. Typically, Viewpoints will challenge existing consensus or discuss a controversial issue to stimulate discussion. Should not exceed 1,500 words, 15 references, 3 authors. A graphical abstract is permitted.

PharmaPulse

European Heart Journal – Cardiovascular Pharmacotherapy publishes short PharmaPulse papers on all topics covered by the scope of the Journal. PharmaPulse can be used to communicate news as well for informal discussion, feedback from conferences or events, or notices from the Working Group on Cardiovascular Pharmacotherapy. Unsolicited PharmaPulse pieces are not accepted.

PharmaPulse papers should not exceed 500 words (including references and the text in figure legends). The paper should not have an abstract, and only 1 image, figure, or table is allowed. Only 5 references are permitted. PharmaPulse papers can have up to 3 authors.

Case Reports

The Journal does not accept case reports. However, case reports can be submitted to European Heart Journal - Case Reports, the international, online-only, fully open access journal of the ESC. The Journal publishes high quality, educationally valuable case reports, images, and quality improvement projects in all aspects of cardiology and cardiovascular medicine. More information is available.

Figures

Figures should be limited to the number necessary for clarity and must not duplicate data given in tables or in the text. Standard submissions should have no more than 8 total figures and tables. Any number exceeding this should be designated as supplementary online-only material. They must be suitable for high quality reproduction and should be submitted in the desired final size so that reduction can be avoided. Figures should be no larger than 125 (height) x 180 (width) mm (5 x 7 inches) and should be submitted under the respective header (“Figure”) and in files separates from that of the main manuscript.

Electronic submission of figures: Figures should be saved in TIFF format at a resolution of at least 300 pixels per inch at the final size for colour figures and photographs, and 1200 pixels per inch for black and white line drawings. While some formats can be converted into TIFFs by the publisher, conversion may alter the tones, resolution and contrast of the image.

Line drawings should be clear: faint shading or stippling will be lost upon reproduction and should be avoided and heavy shading or stippling may appear black. Lines and symbols should be drawn boldly enough to stand reduction to the desired size. For graphs where reduction to one-half in linear dimensions is intended, a suitable thickness for the axis would be 0.3 mm and for the other lines 0.4 or 1.0 mm depending on the complexity of the graph.
The preferred symbols are closed circle, open circle, closed square, open square, closed triangle, and open triangle and should be no smaller than 2 mm (height/diameter

Photographs: Photographs should be of sufficiently high quality, i.e. JPG or TIFF formats with a minimum file size of 1 MB, and 300 dpi. Please ensure that the photographs are of high quality with respect to detail, contrast, and low noise, to enable them to withstand loss of contrast and detail inherent in the production process.

Colour figures: There are no charges for colour figures. Colour plates should be combined to make a single composite figure whenever possible.

Legends: A separate typewritten, double-spaced list of legends of all figures must be supplied and included in the text file. Each legend should contain sufficient explanation to be meaningful without cross-referencing. A scale of the original should be included in the legend unless already indicated in the picture. A description of the symbols used in the figures should be written out in full. Please do not include the character symbol in the legend. All labels used in figures should be in lower case in both the figure and the legend.

Tables

Tables should be typed with double spacing, but minimizing redundant space, and each table should be uploaded as a separate file. Wherever possible, tables should be submitted in portrait - as opposed to landscape - layout. Each table should be numbered in sequence using Arabic numerals. Tables should also have a title above and an explanatory footnote below.

References

References are identified in the text by arabic numerals and numbered in the order cited.

References are typed double spaced on pages separate from the text in the Vancouver style, e.g.:
Birnbaum Y, Sclarovsky S, Mager A, Strasberg B, Rechavia E, ST segment depression in aVL: a sensitive marker for acute inferior myocardial infarction. Eur Heart J 1993; 14: 4-7.

Personal communications, manuscripts in preparation and other unpublished data are not cited in the reference list but are mentioned in the text in parentheses.

Titles of journals should be abbreviated in accordance with Medline. Complete information should be given for each reference, including title of article, abbreviated journal title and inclusive pagination. If there are more than six authors, the first six authors should be listed followed by ‘et al.’.

Supplementary Material

Supporting material that is not essential for inclusion in the main text of the manuscript, but would benefit the reader, can be made available as supplementary material. The material should not be essential to understanding the conclusions of the paper, but should contain data that is additional or complementary and directly relevant to the article content. Such information might include more detailed methods, extended data sets/data analysis, list of investigators, or additional figures.

All supplementary data must be provided in suitable electronic formats (more information on the EHJ website). All material to be considered as Supplementary data must be submitted at the same time as the main manuscript for peer review. It cannot be altered or replaced after the paper has been accepted for publication. Please ensure that the material intended as Supplementary data is clearly indicated as such upon submission and is referred to in the main manuscript, where necessary.

Permission to Reproduce Figures

If illustrations or figures are to be duplicated from previously published work, written permission must be obtained from both the publisher and the author, and a credit line indicating the source must be added in the relevant Figure Legend. If text material (250 to 300 words) is to be reproduced from published sources, written permission is required from both publisher and author. For shorter quotations, it is sufficient to add a bibliographic credit. Letters containing permission for the reproduction of either text or illustrations must be included in the manuscript upload. Please indicate if it was not possible to obtain permissions.

If all illustrations and figures in the manuscript are original, have not been previously published and therefore do not require permission to reproduce, please include the following statement in the file uploaded for Permissions Information: “The authors do hereby declare that all illustrations and figures in the manuscript are entirely original and do not require reprint permission.”

Third-Party Content in Open Access papers

If you will be publishing your paper under an Open Access licence but it contains material for which you do not have Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material:

Title of content

Author, Original publication, year of original publication, by permission of [rights holder]

This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.

Licence to Publish

It is a condition of publication in the journal that authors grant an exclusive licence to the European Society for Cardiology (ESC). This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. In assigning the licence, authors may use their own material in other publications provided that the journal is acknowledged as the original place of publication, and Oxford University Press, on behalf of the European Society for Cardiology (ESC), is notified in writing and in advance.

Upon receipt of accepted manuscripts at Oxford University Press, the corresponding author will be invited to complete an online copyright licence to publish form.

Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with you about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication OUP will contact you using the email address you have used in the registration process. Please note that OUP does not retain copies of rejected articles. Please add ehjcvp.oup@aptaracorp.com to your safe senders list to avoid key emails about the publication of your article potentially going into your spam folder.

The European Society of Cardiology may promote and make available to certain parties the finalised version of an article shortly prior to publication in the journal.

Open Access Options for Authors

European Heart Journal - Cardiovascular Pharmacotherapy offers the option of publishing under either a standard licence or an open access licence. Please note that some funders require open access publication as a condition of funding. If you are unsure whether you are required to publish open access, please do clarify any such requirements with your funder or institution.

In signing a standard licence to publish, the corresponding author (on behalf of all authors) grants an exclusive licence to the European Society of Cardiology to publish their paper in European Heart Journal - Cardiovascular Pharmacotherapy. There is no charge to publish under a standard licence.

Should you wish to publish your article open access, you should select your choice of open access licence in our online system after your article has been accepted for publication. You will need to pay an open access charge to publish under an open access licence.

Please note that if you have been invited to submit to the Journal, and you select an open access licence, you will still be required to pay.

Details of the open access licences and open access charges.

OUP has a growing number of Read and Publish agreements with institutions and consortia which provide funding for open access publishing. This means authors from participating institutions can publish open access, and the institution may pay the charge. Find out if your institution is participating and whether your paper is eligible.

To be eligible for one of OUP’s Read and Publish agreements, the corresponding author must provide their qualifying institution as their primary affiliation when they submit their manuscript. After submission, changing the corresponding author in order to access Read and Publish funding is not permissible.

Pre-submission Language Editing

If you are not confident in the quality of your English, you may wish to use a language-editing service to ensure that editors and reviewers understand your paper. Language editing is optional and does not guarantee that your manuscript will be accepted. Edited manuscripts will still undergo peer review by the journal.

Oxford University Press partners with Enago, a leading provider of author services. Prospective EHJ Case Reports authors are entitled to a discount of 30% for editing services at Enago, via the Specialist English Editing Services for Oxford University Press Authors page.

Publication of author’s accepted manuscripts

EHJ-CVP aims to publish authors’ accepted manuscripts on Advance Access page within 2 weeks of receipt at OUP, as long as a licence to publish is signed as soon as possible (a link will be sent in the initial email when a paper is sent to OUP). The accepted manuscript will be published in PDF format.

Manuscripts are then copyedited, typeset, proofed out, and corrected. Once the manuscripts are finalized, the uncorrected manuscripts are replaced with the final corrected articles in HTML and PDF format.

Format Free Submission

If preferred, authors may submit their manuscript without journal-specific formatting at initial submission.

Authors are still required to:

Answer all questions in the online submission form
Submit all parts of the manuscript, including the abstract, figures, figure legends, and supplementary files. Figures may be embedded in the manuscript file or uploaded separately
State all conflicts of interest (if there are no conflicts to declare, the authors should state “Conflict of Interest: none declared”)
For articles which require a declaration of informed patient consent (see Human subjects and patient consent above), include a statement addressing informed patient consent as part of the manuscript under the heading “Consent”
Include page numbers in the manuscript file

If requested to submit a revised version of the manuscript, authors should refer to Manuscript Preparation for formatting instructions.

Proofs

Page proofs will be submitted to the corresponding author electronically. These should be checked thoroughly for any changes or typographic errors.

It is the publisher’s intent to review and correct the proofs and publish the accepted work as soon as possible. To achieve this, it is mandatory that all corrections are returned to OUP within 3 days. Subsequent additional corrections will not be possible, hence please ensure that all amendments are marked up comprehensively in the proofs.

Preprints and self-archiving

Authors retain the right to make an Author’s Original Version (preprint) available through various channels and this does not prevent submission to the Journal. At initial submission, authors should indicate if any preprint is available in a server or repository. If accepted, the authors are required to update the status of any preprint, including adding the published paper’s DOI. For full details on allowed channels and updating your preprint, please see our Author self-archiving policy.

Authors of all article types, excluding ESC Guidelines, may enter their Accepted Manuscript (the final draft after peer review but before copyediting, typesetting and proof correction, also called the “post-print”) in PubMed Central, other subject repositories, or institutional repositories providing that the public availability of the manuscript is delayed by 12 months after the first online publication.

More information about this policy

Author Toll-Free Link

All corresponding authors will be provided with a free access link to their article upon publication. The link will be sent via email to the article’s corresponding author who is free to share the link with any co-authors. Please see OUP’s Author Self-Archiving policy for more information regarding how this link may be publicly shared depending on the type of license under which the article has published.

Post-publication corrections

The Publisher will only make changes to published papers if the publication record is seriously affected by the academic accuracy of the published information.

Changes to published papers are always accompanied by a formal correction notice. This applies to papers on Advance Access and those published within an issue. This means that any change carried out to a paper already published online will have a corresponding correction published with its own separate DOI. The notice will be published online at the earliest opportunity (on the Journal’s Advance Articles page if possible, otherwise in the earliest available issue), and will be clearly linked to the paper being corrected. A link will also appear on the paper being corrected, notifying readers that a correction has been published.

Changes cannot be made to archival papers (i.e. published online more than 12 months before). In such instances a correction will be published explaining the error, but the paper will not be updated. The correction will be published online with links to the original paper as described above.

To submit a correction the corresponding author should email journals.corrections@oup.com.

OUP’s full corrections policy is available here.

Retractions

The Journal subscribes to the COPE Retraction Guidelines, which outlines appropriate use cases for retractions. The Journal also has the option of consulting the ESC Journal Family Ethics Committee.

Contact Us

For any questions or feedback please contact the Editorial Office: ehjcvp.editorialoffice@oup.com.